An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202

A. Vogel, V. Sahai, A. Hollebecque, G. M. Vaccaro, D. Melisi, R. M. Al Rajabi, A. S. Paulson, M. J. Borad, D. Gallinson, A. G. Murphy, D. Y. Oh, E. Dotan, D. V. Catenacci, E. Van Cutsem, C. F. Lihou, H. Zhen, M. L. Veronese, G. K. Abou-Alfa

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Fibroblast growth factor receptor 2 (FGFR2) fusions and rearrangements are clinically actionable genomic alterations in cholangiocarcinoma (CCA). Pemigatinib is a selective, potent, oral inhibitor of FGFR1-3 and demonstrated efficacy in patients with previously treated, advanced/metastatic CCA with FGFR2 alterations in FIGHT-202 (NCT02924376). We report final outcomes from the extended follow-up period. Patients and methods: The multicenter, open-label, single-arm, phase II FIGHT-202 study enrolled patients ≥18 years old with previously treated advanced/metastatic CCA with FGFR2 fusions or rearrangements (cohort A), other FGF/FGFR alterations (cohort B), or no FGF/FGFR alterations (cohort C). Patients received once-daily oral pemigatinib 13.5 mg in 21-day cycles (2 weeks on, 1 week off) until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) in cohort A assessed as per RECIST v1.1 by an independent review committee; secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Results: FIGHT-202 enrolled 147 patients (cohort A, 108; cohort B, 20; cohort C, 17; unconfirmed FGF/FGFR alterations, 2). By final analysis, 145 (98.6%) had discontinued treatment due to progressive disease (71.4%), withdrawal by patient (8.2%), or adverse events (AEs; 6.8%). Median follow-up was 45.4 months. The ORR in cohort A was 37.0% (95% confidence interval 27.9% to 46.9%); complete and partial responses were observed in 3 and 37 patients, respectively. Median DOR was 9.1 (6.0-14.5) months; median PFS and OS were 7.0 (6.1-10.5) months and 17.5 (14.4-22.9) months, respectively. The most common treatment-emergent AEs (TEAEs) were hyperphosphatemia (58.5%), alopecia (49.7%), and diarrhea (47.6%). Overall, 15 (10.2%) patients experienced TEAEs leading to pemigatinib discontinuation; intestinal obstruction and acute kidney injury (n = 2 each) occurred most frequently. Conclusions: Pemigatinib demonstrated durable response and prolonged OS with manageable AEs in patients with previously treated, advanced/metastatic CCA with FGFR2 alterations in the extended follow-up period of FIGHT-202.

Original languageEnglish
Article number103488
Pages (from-to)103488
JournalESMO Open
Volume9
Issue number6
DOIs
StatePublished - Jun 2024

Keywords

  • fibroblast growth factor receptor
  • intrahepatic cholangiocarcinoma
  • next-generation sequencing
  • pemigatinib
  • precision medicine
  • targeted therapy

Fingerprint

Dive into the research topics of 'An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202'. Together they form a unique fingerprint.

Cite this